Black Rock Inc. Affimed N.V. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.32 - $0.62 $306,817 - $594,458	-958,804 Reduced 83.32%	191,956 $119,000
Q3 2023 Nov 13, 2023	SELL	$0.46 - $0.65 $36,742 - $51,918	-79,874 Reduced 6.49%	1,150,760 $552,000
Q2 2023 Aug 11, 2023	SELL	$0.57 - $1.08 $3.98 Million - $7.54 Million	-6,976,876 Reduced 85.01%	1,230,634 $738,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.29 $16,225 - $31,713	24,584 Added 0.3%	8,207,510 $6.16 Million
Q4 2022 Feb 13, 2023	BUY	$1.1 - $2.45 $489,722 - $1.09 Million	445,202 Added 5.75%	8,182,926 $10.1 Million
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $404,442 - $685,075	-206,348 Reduced 2.6%	7,737,724 $15.9 Million
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $2.77 Million - $5.93 Million	1,219,856 Added 18.14%	7,944,072 $22 Million
Q1 2022 May 12, 2022	SELL	$3.69 - $5.65 $460,390 - $704,933	-124,767 Reduced 1.82%	6,724,216 $29.4 Million
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $380,695 - $501,213	70,893 Added 1.05%	6,848,983 $37.8 Million
Q3 2021 Nov 09, 2021	BUY	$5.54 - $7.51 $244,607 - $331,589	44,153 Added 0.66%	6,778,090 $41.9 Million
Q2 2021 Aug 11, 2021	BUY	$7.78 - $11.4 $52.4 Million - $76.8 Million	6,733,937 New	6,733,937 $57.2 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $391M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.